India, May 20 -- Shaily Engineering Plastics announced that its strategic partner Orbicular Pharmaceutical Technologies in partnership with its Customer has launched a generic version of Semaglutide injection in Canada, incorporating Shaily's proprietary spring-driven ShailyPen Neo' pen platform. The combination product has been commercially available in India since March 2026 and has received USFDA Tentative Approval.ShailyPen Neo' is among a rare class of commercially available spring-driven pen injectors globally ' a high-performance, variable and fixed dose platform offering full compatibility with ISO-standard 3 mL cartridges (3 mL and 1.5 mL fill). Shaily's role in this program relates to full design and development, and manufacturing...